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ABSTRACT
Two meetings of the World Health Organization (WHO)—in 1999 and 2002—had examined the 
potential use of oral cholera vaccines (OCVs) as an additional public-health tool for the control of 
cholera. In the light of the work accomplished since 2002, WHO convened a third meeting to re-
examine with a group of experts the role that OCVs might play in preventing potential outbreaks of 
cholera in crisis situations and to discuss the use of OCVs in endemic settings. The aim of the meet-
ing was to agree a framework for the recommendations of WHO on these subjects and to consider 
the pertinence of further demonstration projects in endemic settings. The meeting addressed key is-
sues, including currently-available vaccines, surveillance, and cholera-control measures in complex 
emergencies, and past experiences of using OCVs. More than 40 participants took part in the dis-
cussions, representing cholera-prone countries, humanitarian organizations, scientific institutions, 
United Nations agencies, and WHO. The experts agreed that when considering the use of OCVs in 
emergencies, a multidisciplinary approach is essential and that the prevention and control of cholera 
should be envisaged within the larger context of public-health priorities in times of crisis. As for the 
use of OCVs in endemic settings, all participants acknowledged that further data need to be col-
lected before a clear definition of endemicity and potential vaccination strategies can be established. 
Results of further studies on the vaccines per se are also awaited. Recommendations relating to the 
use of OCVs (a) in complex emergencies and (b) in endemic settings were elaborated, and a decision-
making tool for assessing the pertinence of use of OCVs in emergency settings was drafted. The document 
was finalized by an ad-hoc working group convened in Geneva on 1 March 2006 and is now avail-
able for field-testing. After testing, that should be carried out with the involvement of WHO and 
feedback from field partners, the decision-making tool will be adapted and disseminated.
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INTRODUCTION
Although well-known since the nineteenth cen-
tury, cholera remains the most feared and stig-
matized diarrhoeal disease. As a waterborne 
disease, it mainly affects the poorest and the 
most vulnerable populations who live without 
access to safe water and proper sanitation. The 
burden it imposes on healthcare systems and on 
its victims is enormous. Furthermore, countries, 
fearful of possible commercial sanctions that 
would prevent the export of food products, are 
often reluctant to report cases and seek support. 
Heavy death tolls are regularly reported and, in 
disaster situations, the possibility of cholera fre-
quently triggers panic—even when the risk of 
outbreak appears extremely limited.
Implementation of the prevention and control 
measures usually recommended, including im-
provement of water and sanitation, remains 
a challenge in both urban slums and crisis situa-
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tions. To date, there has been no concrete global 
improvement despite efforts made at the coun-
try level; the incidence of disease has even in-
creased in recent years. Predicting potential 
outbreaks remains difficult and is often compli-
cated by the lack of data on trends and patterns 
of the disease over time.
It  is  clear  that  additional  public-health  tools, 
such as vaccines, can play a critical role in the 
control of cholera. The pre-emptive use of oral 
cholera vaccines (OCVs) in emergency situations 
was recommended by the World Health Organi-
zation (WHO) in 1999, and this general recom-
mendation remains valid  (1,2). However, vac-
cines must be used in appropriate circumstances, 
where they can provide a definite benefit and 
will not jeopardize the response to other health 
priorities. Identifying the population at risk of 
epidemic cholera is, therefore, a key element in 
considering the use of OCVs, as is the cost-effec-
tiveness of such an intervention. Several mass-
vaccination campaigns have already been carried 
out in crisis situations, and a group of experts, 
convened in a WHO meeting, used the evidence 
provided by these interventions as the basis for 
developing assessment tools and recommenda-
tions for the use of OCVs in mass-vaccination 
campaigns and to identify the possible constraints 
and limitations. This meeting, held in Cairo, 
Egypt, on 14-16 December 2005, intended to es-
tablish a framework for recommendations on the 
use of OCVs in complex emergencies and natural 
disasters and in endemic settings (3). More than 
40 participants were present, representing chol-
era-prone countries that had already used or ex-
pressed interest in using OCVs, humanitarian 
organizations, scientific institutions, United Na-
tions agencies, and WHO. A vaccine manufac-
turer was granted an observer status, but did not 
attend sessions aimed at developing recommen-
dations on the use of OCVs. 
Available vaccines and new developments
Because  of  its  low-protective  efficacy  and  the 
frequent occurrence of severe adverse reactions, 
the early parenteral cholera vaccine was never 
recommended for use (4). To date, two oral vac-
cines  have  been  licensed  internationally.  One 
consists of killed whole-cell Vibrio cholerae O1 
with purified recombinant B-subunit of cholera 
toxin (WC/rBS). It is administered in two doses, 
with an interval of 10-14 days between the dos-
es. A large volume (75-150 mL) of liquid is need-
ed for administration, meaning that the vaccine 
cannot be given to children aged less than two 
years. Protection starts 10 days after the ingestion 
of the second dose and has been shown to reach 
85-90% after six months in all age-groups, dec-
lining to 62% at one year among adults (5). This 
vaccine, currently produced in Sweden, has been 
granted WHO prequalification.
The second licensed vaccine consists of an at-
tenuated, live, and genetically-modified V. chole-
rae O1 strain (CVD 103-HgR) (6). It is adminis-
tered in a single dose to individuals aged two 
years and over; protection starts eight days after 
ingestion (7). Although a 95% seroconversion 
and protection was observed during a challenge 
study, a large field trial undertaken in Indone-
sia, in circumstances that complicated interpre-
tation, failed to demonstrate convincing protec-
tion (8). The manufacturer stopped production 
in 2004, and the vaccine, although licensed, is cur-
rently unavailable. 
Technology transfer to Viet Nam has generated a 
variant of the killed whole-cell vaccine contain-
ing no recombinant B-subunit, i.e. WC vaccine. 
This vaccine,  currently produced and used only 
in Viet Nam, is given in two doses at an interval 
of 10-14 days, without the need for a buffer so-
lution. The protective efficacy of a first-genera-
tion monovalent (anti-O1) Vietnamese cholera 
vaccine was shown to be 66% (68% in children) 
8-10 months after vaccination (9). Killed O139 
whole cells were added to the Vietnamese vac-
cine following the emergence of the new form 
of epidemic cholera caused by this serogroup. A 
study found the bivalent vaccine to be safe and 
immunogenic in adults and children aged one 
year and older (10,11). Technology transfer to 
India, that could lead to a WHO prequalification, 
is underway.
A number of other live oral vaccines are under 
development in the USA (12) and in Cuba (13). 
In addition, research is currently being conducted 
on parenteral conjugate vaccines and on ways 
to improve vaccine formulation to ease the nu-
merous logistics constraints, particularly acute 
in emergencies, linked to the mode of admin-
istration of the vaccine presently available. In-
deed, the limitations of the WC/rBC vaccine in 
emergency settings, where logistic and practical 
constraints abound, are numerous, but its use in Chaignat CL and Monti V Oral cholera vaccines in complex emergencies
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a routine context is much more easily managed 
(14). Since efficacy requirements may be lower 
in an emergency context, vaccines specifically 
designed for emergency public-health applica-
tions might be considered (15,16).
Potential effect of herd protection
In researching the public-health impact of chole-
ra immunization, the concepts of herd protec-
tion and herd amplification, which arose from 
recent environmental studies, are important is-
sues that merit examination. When dealing with 
a killed vaccine, the term herd protection is pre-
ferred to herd immunity as unvaccinated persons 
do not develop antibodies. If these concepts prove 
to be sound, herd protection may have a ma-
jor role in increasing the impact of vaccination 
and reducing the cost and burden of cholera—
factors that are essential elements in any consid-
eration of the future use of cholera vaccines.
A new analysis of the 1985 cholera vaccine trial 
in Bangladesh established that there was an addi-
tional indirect protective effect among both vac-
cinated and non-vaccinated individuals when a 
high proportion of the population was vaccinat-
ed and a possible reduction of the incidence of 
cholera in all age-groups (17). The public-health 
impact of killed OCV may, thus, have been un-
derestimated  in  the  past,  as  only  the  conven-
tional protection efficacy of the vaccine was 
measured and not the potential effect of herd 
protection. Further studies are, therefore, needed 
to precisely evaluate the effect of herd protec-
tion, especially as a number of circumstances can 
have induced a bias (density of population and 
dwellings, environmental factors, health-educa-
tion programmes, and microbiological aspects of 
the disease) (18). 
The design of future vaccine-evaluation and ef-
ficacy studies will need to consider the role of 
herd protection. The hypothetical existence of 
significant herd protection will have implica-
tions  for  the  choice  of  target  populations  for 
cholera vaccination. It is likely that access to the 
vaccine might be enhanced for groups who do 
not usually have access to or seek treatment. It 
remains to be determined how these elements 
will influence the development of strategies that 
focus on reaching a particular threshold level of 
vaccination to achieve an acceptable level of 
protection in a community.
Surveillance in complex emergencies
Several definitions describe the blurred concept 
of complex emergencies. In this meeting, a prag-
matic public-health perspective was adopted, 
aiming principally at highlighting the health 
priorities and challenges. All participants agreed 
to define complex emergencies in the following 
terms:
•  a large part of the population is affected, 
leading to potential massive movements of 
populations;
•  coping capacities of the local and national 
authorities are overwhelmed by the magni-
tude of man-made or natural disasters; and
•  numerous national and international actors 
may participate in the relief efforts.
The first consequence of a complex emergency is 
the upheaval of usual life and the emergence of 
‘new’ vulnerable population groups. Lack of ac-
cess to basic services and healthcare, lack of food, 
and displacement have an impact on the health 
status of the population. Restoring an acceptable 
health status presents a number of varied chal-
lenges: prioritization of health issues, coordination 
of the numerous actors involved, and timeliness 
when urgent action is required. The decision-
making and preparatory phase is often extremely 
short, and access to vulnerable populations is fre-
quently limited by specific geographical difficul-
ties, further natural disasters, a volatile security 
environment, or mass population movements. 
People living in overcrowded camps with poor en-
vironmental status are exposed to a higher risk of 
transmission of cholera if V. cholerae is endemic 
in the area or has been introduced. Moreover, un-
controlled rumours and panic are often rife: in 
every catastrophe, false beliefs regarding plagues 
and epidemics transmitted by dead bodies tend to 
be widespread. In such contexts, cholera remains, 
rightly or wrongly, the disease most feared by the 
population and by the authorities. 
In all cases, the occurrence, spread, and extent of 
an outbreak of cholera are extremely difficult to 
predict. They depend on a multiplicity of aspects, 
including local endemicity, living conditions, 
forced or voluntary movements of population, 
environmental and cultural factors, and the effec-
tiveness of any control measures put in place. In 
some endemic situations, where outbreaks tend to 
occur at regular intervals, seasonal recrudescence Chaignat CL and Monti V Oral cholera vaccines in complex emergencies
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can be anticipated, provided that enough epide-
miological data are known. The establishment of 
an epidemiological surveillance system that will 
provide baseline data and trends is, thus, a key ele-
ment in directing the potential use of OCVs. How-
ever, if the early warning system is a challenge in 
many countries, surveillance and gathering of data 
in a complex emergency are even more problem-
atic. One of the main difficulties is to establish a 
system that is both reactive and sustainable; this 
is particularly tricky when resources are scarce and 
security cannot be ensured. For cholera, the in-
troduction of a rapid, easy-to-use, and affordable 
diagnostic test, currently under development, will 
be critical. Nevertheless, the task is complicated by 
the stigma attached to the disease and the reluc-
tance of many to report cases for fear of travel and 
trade sanctions, a fact that impacts negatively on 
surveillance. 
An early warning system using standard case defi-
nition is essential to trigger the alert promptly, an 
element particularly critical in high-risk situations, 
such as in refugee camps and urban slums, and 
among displaced populations. The definition of 
outbreak should take into account essential back-
ground information, including the occurrence of 
previous cases or outbreaks and endemicity.
The following definitions used by Médecins sans 
Frontières (MSF) are a good example:
•  in endemic areas: doubling of cases over three 
consecutive weeks or increase in cases com-
pared to the previous year;
•  in non-endemic areas: an increasing number 
of confirmed cases;
•  an increasing number of adults dying of wa-
tery diarrhoea.
Water and sanitation in complex emergencies
Other elements closely relating to the contain-
ment of outbreaks of cholera are water supplies 
and sanitation status of populations at risk. The 
example of Darfur, Sudan, offers valuable indica-
tions of the cost, impact, and challenges of water 
and sanitation projects in complex emergencies 
and of the role of such projects in preventing out-
breaks of cholera. At the beginning of the human-
itarian intervention in May 2004, only 20% of the 
internally-displaced persons (IDPs) living in areas 
reachable by the United Nations agencies had 
access to adequate water, and only about 5% to 
proper sanitation; by September 2005, 16 months 
later, these figures had risen to 52% and 76% res-
pectively. These numbers are not calculated ac-
cording to the Sphere standards and are provided 
for information only; they cannot be considered 
an accurate indicator of water and sanitation sup-
plies to a population and do not describe the actu-
al conditions faced by the people. Clearly, despite 
the enormous efforts provided by all humanitari-
an bodies active in the field for more than a year, a 
significant number of people still lacked access to 
minimum water supply and sanitation facilities. 
This situation serves also to illustrate the obstacles 
faced by humanitarian workers—lack of human 
and financial resources, logistic constraints, limi-
ted access to beneficiaries, and poor planning and 
coordination—that prevent sustained implemen-
tation and maintenance.
The exact cost of improved water and sanitation is 
difficult to establish; a comparison of the costs of 
different interventions is, therefore, needed. The 
cost–benefit of improved water and sanitation, 
from both health and socioeconomic perspectives, 
is seen mainly in the reduction of waterborne dis-
eases—cholera and others—which lowers health-
related costs and reduces morbidity.
Usually recommended cholera-control 
measures
Once an outbreak is detected, the usual interven-
tion strategy aims at reducing mortality—ideally 
below 1%—by ensuring access to treatment and 
controlling the spread of disease. To achieve this, 
all partners involved should be properly coordi-
nated and those in charge of water and sanitation 
must be included in the response strategy. The 
main tools used for the treatment of cholera are:
•  proper and timely rehydration in cholera-treat-
ment centres and oral rehydration corners;
•  specific training for proper case management, 
including avoidance of nosocomial infections;
•  sufficient  prepositioned  medical  supplies  for 
case management, e.g. diarrhoeal disease kits;
•  improved access to water, effective sanitation, 
proper waste management, and vector control;
•  enhanced hygiene and food safety practices; 
and
•  improved communication and public infor-
mation.
Among these measures, the provision of safe wa-
ter and sanitation in emergencies is a formidable Chaignat CL and Monti V Oral cholera vaccines in complex emergencies
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challenge but remains the critical factor in reduc-
ing the impact of outbreaks of cholera. Recom-
mended control methods, including standardized 
case management, have proved to be effective in 
reducing the case-fatality rate. A comprehensive 
multidisciplinary approach should, therefore, be 
adopted for dealing with a potential outbreak of 
cholera, and the use of OCVs should be integrat-
ed when it can make a difference. Cost-effective-
ness of such interventions needs clarification. Al-
though the exact cost of different interventions 
is difficult to establish, they still need to be inves-
tigated and compared.
Use of OCVs in crisis situations: recent examples
The value and potential impact of OCVs in dif-
ferent settings were debated on the basis of evi-
dence accumulated since 2002. The examples of 
two mass-vaccination campaigns—carried out 
with WHO support in 2004 in Darfur and in 2005 
in Aceh—were examined and compared. Both the 
campaigns took place during complex emergen-
cies, but the nature of the emergencies and of the 
target populations, the simultaneous implementa-
tion of programmes to address other public-health 
priorities, the location of the campaigns, and the 
partners involved were widely different. 
In Darfur, 87% of 53,537 people targeted—in-
ternally-displaced people accommodated in two 
camps where water supplies and sanitation were 
poor—received two doses of the WC/rBS. The 
campaign was completed in about six weeks, 
and the direct costs of the campaign reached 
US$ 336,527, or US$ 7 per fully-immunized per-
son. In Aceh, 69.3% of 78,870 people initially 
targeted—people displaced by the tsunami and 
scattered around large areas—had received two 
doses of the same vaccine. The campaign was 
completed in more than six months, and the di-
rect costs of the campaign reached US$ 958,649, 
or US$ 18 per fully-immunized person (19).
The evidence from Darfur indicates that a small-
scale mass-vaccination campaign with OCVs is 
feasible provided that there is a strong political 
commitment, easy access to the target popula-
tion, that is accommodated in closed IDP camps, 
widespread community mobilization, and in-
volvement of all partners. The Aceh campaign, 
however, points clearly to the limitations of us-
ing a two-dose vaccine in the context of a natural 
disaster. Enormous logistics and operational con-
straints greatly delayed the implementation of 
the vaccination—it took more than six months 
to complete it—and increased the costs dispro-
portionately. Furthermore, insufficient cold chain 
and the short shelf-life of vaccines led to an over-
all vaccine wastage of 11.7%. The feasibility of 
large-scale interventions is questionable: future 
campaigns will require solutions to the many dif-
ficulties encountered, and a suitable methodolo-
gy is needed to guide the decision-making pro-
cess of governments wishing to consider the use 
of OCVs. The main lessons learned from Aceh 
and Darfur can be summarized as follows:
•  An OCV campaign is feasible in natural and 
man-made disasters, provided that political 
commitment and good social mobilization 
can be achieved, good logistics can be en-
sured, and sufficient funds are available. The 
target population should be well-defined, lo-
calized in a small area, and stable.
•  A mass OCV-vaccination campaign serves to 
highlight important deficiencies in water and 
sanitation  coverage  and  to  build  the  com-
mitment of stakeholders and implementing 
agencies.
•  The use of OCV is only one part of a set of 
comprehensive public-health preventive in-
terventions.
Logistics and planning challenges for use of 
OCVs in crisis situations
These two recent examples show that the use 
of the two-dose OCV in emergency settings can 
be seriously challenged by various shortfalls and 
the onerous logistics involved. Several character-
istics of the vaccine are less than ideal for emer-
gency settings, including its shelf-life, required 
storage conditions (cold-chain, at between +2 °C 
and +8 °C), and volume (25 times greater than 
measles vaccine); moreover, its mode of admin-
istration demands the availability of significant 
volumes of clean water and requires the target 
population to be reached twice within a short 
time (10-14 days).
Although logistic constraints can often be over-
come, they usually lead to delays in implemen-
tation and significant increases in cost. In each 
situation, the cost-benefit must be thoroughly 
assessed and the whole campaign planned in 
detail. Experience in planning and implement-
ing mass OCV-vaccination campaigns in various Chaignat CL and Monti V Oral cholera vaccines in complex emergencies
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settings since 1999 has helped identify the fol-
lowing 12 principal challenges:
•  During natural disasters or other complex emer-
gencies, basic infrastructures are damaged and 
disrupted, the population is vulnerable and sub-
ject to continual threats, and healthcare person-
nel are scarce.
•  Access to target populations is often limited by 
geographical factors, destruction of roads, cli-
matic conditions, potential aftershocks, and a 
volatile security situation.
•  To deal with perceived but unconfirmed risks 
that may not be based on solid evidence, a risk 
assessment should be carried out: available epi-
demiological data, living conditions faced by 
the population, climatic conditions, environ-
mental management, and cultural behaviours 
are the key elements to be examined.
•  The target population may be difficult to iden-
tify with precision when there are continual 
population movements.
•  Thorough planning and preparation are cru-
cial: coordination with partners is impor-
tant, as are the assignment of responsibilities 
and good logistic arrangements. Functioning 
communications, training of field staff, ade-
quate health education, and social mobiliza-
tion programmes are other elements to be 
taken into account.
•  During the implementation phase, monitor-
ing of the operations, ensuring timely deliv-
ery of supplies, and maintaining communi-
cation with community leaders are crucial.
•  Logistics must be thoroughly planned and 
closely monitored throughout the campaign, 
with the principal focus on transport and 
storage of supplies, transport of field teams, 
cold-chain facilities, management of wastes, 
and reliable telecommunications.
•  An efficient surveillance system is vital for the 
early detection of any cholera cases that occur 
after the vaccination and for the implementa-
tion of specific control measures.
•  Sustained improvement in environmental man-
agement, access to safe water and proper sanita-
tion, and adequate hygiene and food safety are 
essential components of a comprehensive con-
trol strategy for cholera.
•  Health education constitutes a long-term ef-
fort and needs to address the vaccine itself, the 
vaccination campaign, and food hygiene, and 
water and environmental safety. Involvement 
of the community is critical to ensure effective 
social mobilization for the campaign and to 
avoid culturally-inappropriate activities. 
•  Problems with vaccine availability, affordabili-
ty, and packaging (if not adequately designed) 
can prevent smooth implementation. Before 
the campaign begins, ad-hoc solutions must 
be found.
•  The reality of a vaccination campaign inevita-
bly differs from what was originally planned 
and expected. A detailed timeline helps anti-
cipate potential hindrances and plan alterna-
tive solutions.
Clearly, a mass-vaccination campaign cannot be 
improvised at the last moment—it needs careful 
advance preparation. If time constraints do not 
allow for proper planning, for instance if an out-
break is about to start or has already started, the 
use of OCVs may not be appropriate. Experience 
shows that, once an outbreak of cholera has be-
gun, a reactive vaccination campaign with a 
two-dose vaccine is almost impossible.
In addition, the use of OCVs needs to be posi-
tioned within the larger context of other public-
health priorities. It should be additional to health 
education and improvements in water and sanita-
tion, not the sole intervention, and should never 
be seen as a substitute for preparedness for out-
breaks of cholera—pre-positioning of supplies for 
case management, health education, and improve-
ments in water supply and sanitation. In settings 
where a population is inaccessible for extended 
periods (for example, in detention facilities) or 
when the water and sanitation status cannot be 
rapidly improved, the use of OCVs may be a defi-
nite benefit. The use of two-dose OCV is easier in 
closed settings (refugee and IDP camps, detention 
facilities, etc.), where population movements are 
limited and can be better controlled than in open 
settings, such as the spontaneous IPD settlements 
found in Aceh. The feasibility of scaling up inter-
ventions remains to be proved, and the cost-bene-
fit should be further analyzed. For the time being, 
the two-dose vaccine and the logistics associated 
with its use remain very expensive.
Use of OCVs in endemic settings
A demonstration project, carried out in Beira, Mo-
zambique, showed that a mass-vaccination cam-Chaignat CL and Monti V Oral cholera vaccines in complex emergencies
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paign using OCVs was feasible (20,21), acceptable, 
and effective (22) for at least six months. Around 
57% of the target population—inhabitants of Es-
turro neighbourhood—received two doses of the 
WC/rBS, and a case-control study conducted in 
2004, involving 43 patients with cholera, demon-
strated a protective efficacy of 78%. Nevertheless, 
the study left a number of important questions 
unanswered, including duration of the protection, 
existence of herd protection, protection within the 
HIV-positive population, and cost-effectiveness. 
Globally, studies carried out in different coun-
tries suggest that the proper definitions of chole-
ra cases and of endemicity need to be further 
defined. Differences in methodologies and in 
attitudes of national authorities towards chole-
ra can result in different approaches to the dis-
ease—including the prevention measures to be 
adopted and the potential use of OCVs. It is, 
therefore, important to find a definition of chole-
ra endemicity that can be widely adopted. A 
threshold of one case per 1,000 people has been 
proposed, but has yet to be universally accepted. 
Epidemiological data still need to be collected: 
lack of these data is an obstacle for advocating 
the use of OCVs. On the other hand, increas-
ing treatment costs and rising antimicrobial 
resistance make development of a vaccination 
strategy for endemic settings highly desirable, 
provided that the vaccine can be formulated for 
administration to children aged less than two 
years, can protect against both V. cholerae O1 
and O139 serotypes, and is cost-effective.
Indeed, the cost per death averted and per hos-
pitalization averted declines with the increasing 
incidence of cholera: even a very inexpensive 
vaccine becomes cost-effective only when the 
incidence exceeds 1/1,000. By comparison, the 
same model estimates that case management, if 
provided through routine hospital or treatment 
centre care, costs about US$ 350 per death avert-
ed. Even moderately-inexpensive vaccines, there-
fore, quickly become too expensive. For example, 
a vaccine requiring two doses at US$ 3 per dose 
will cost more than US$ 3,000 per death averted, 
even where the incidence is high. By contrast, a 
vaccine priced at US$ 0.40 will cost less than US$ 
400 per death averted, which compares favour-
ably with case management, especially as hospi-
tal and treatment costs will decrease. In addition, 
models have been developed to determine the 
key variables, the most important of which ap-
pear to be the incidence of cholera and the cost 
of the vaccine, including delivery cost (23). The 
efficacy of vaccines seems of less importance. 
Vaccines should, thus, be inexpensive and easy 
to administer and should be provided to inhabi-
tants of high-risk areas. Furthermore, a vaccine 
marketed over-the-counter may be economic for 
health ministries, since it would shift the vaccine 
costs to the consumer rather than to the govern-
ment. Finally, the adoption of vaccination strate-
gies will not replace treatment facilities.
Countries interested in using OCVs in endemic 
settings will need to design vaccination strategies 
that will achieve the best possible coverage. Differ-
ent strategies can be envisaged, but all should be 
based on mapping of risk and should take account 
of high-risk groups (particular age-groups and vul-
nerable populations living in specific geographical 
areas) and feasibility. The sustainability of vacci-
nation strategies is the paramount consideration: 
mass-vaccination campaigns that are not sustain-
able may be useless and possibly counter-produc-
tive.
Experts present in the meeting recognized that a 
number of issues still need to be studied, includ-
ing the efficacy of OCVs in populations with a 
high proportion of HIV-positive individuals, a 
definition of endemicity, and the cost-effective-
ness of the vaccine. Work should also be done on 
vaccination strategies. Although the use of OCVs 
in endemic settings can be supported in principle, 
detailed recommendations remain to be worked 
out. The group recommended the synergistic use 
of control measures other than vaccine, namely 
improvement of water supply and sanitation and 
health education. Demonstration projects should 
yield additional useful data.
Pertinence of a stockpile of cholera vaccines 
The example of the International Coordinating 
Group on Meningitis (ICGM) for supply of an-
timeningococcal vaccine was taken to assess the 
pertinence of creating a stockpile of cholera vac-
cines. In view of the numerous difficulties and 
high financial costs involved, the advantages 
and disadvantages of creating a stockpile should 
be examined in detail, and an adequate stock ro-
tation should be ensured.
The only OCV currently available on the inter-
national market is manufactured by the Swedish 
company—SBL Vaccines—under the commercial 
name Dukoral®. To date, the vaccine is not widely 
used, although licensed in 45 countries. Produc-Chaignat CL and Monti V Oral cholera vaccines in complex emergencies
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tion costs remain high and are not covered by the 
price of the vaccine—up to €5 (US$ 6.10) a dose. 
Maintained in a cold-chain, Dukoral® has a shelf-
life of three years; according to the manufacturer, 
it can be kept at 25 °C for three months and at 
37 °C for one month, but these storage conditions 
were not recognized in the prequalification pro-
cess. 
The WHO recommendations of 1999 proposed 
the establishment of a stockpile of two million 
doses of cholera vaccine for use in endemic and 
emergency settings. However, because of the lack 
of precise guidelines for the use of OCV, the high 
costs involved, and the limitations that became 
apparent during mass-vaccination projects carried 
out in the 2000-2005 period, the stockpile was 
never implemented. Moreover, the only current 
OCV manufacturer has clearly stated that, with-
out firm orders, its limited production capacities 
will not be expanded. Thus, until recommenda-
tions and guidelines are issued and promoted, 
the issue of a stockpile is not relevant. The sub-
ject will be raised with partners and donors after 
field validation of the recommendations—and, 
in particular, of the decision-making tool—when 
countries concerned express their willingness to 
implement large-scale mass vaccinations or to in-
troduce OCVs into their routine expanded pro-
gramme of immunization (EPI).
CONCLUSION
The group of experts convened in Cairo agreed 
on two sets of recommendations, dealing respec-
tively with: (a) public-health use of OCVs in en-
demic settings, and (b) public-health use of OCVs 
in complex emergencies. Although several aspects 
of the disease itself, and of the vaccines to fight 
it, still need to be clarified—a concerted thresh-
old of cholera endemicity being on the top of the 
list—the recommendations summarized below 
will guide those who consider a large-scale use of 
OCVs (the full text can be found in Annexure 1). 
Future progress in research, particularly in vaccine 
formulation, will call for further consultation and 
possible amendment of these recommendations; 
it will be examined in due course.
Summarized recommendations for the use of 
OCVs in complex emergency settings
The relevance of oral cholera vaccination should 
be examined in the light of other public-health 
priorities. It should be linked to improved surveil-
lance and enhanced water and sanitation pro-
grammes. A high-level commitment by all stake-
holders and national authorities is critical, and a 
multidisciplinary approach is essential. The cur-
rent internationally-available pre-qualified vaccine 
is not recommended once an outbreak of cholera 
has started and should not be performed if basic 
favourable conditions are not present. A decision-
making tool, developed by an ad-hoc group, is 
intended to assist those in charge of risk assess-
ments  and  subsequent  decisions.  This  tool  still 
needs to be validated in field conditions.
Summarized recommendations for the use of 
OCVs in endemic settings
Despite the limitations of the currently-available 
vaccine, the use of OCVs in certain endemic situ-
ations should be recommended, and guidelines 
should be developed. Such use must be comple-
mentary to existing strategies for cholera control, 
such as safe water and sanitation, case manage-
ment, and health education of the community. 
Without jeopardizing the issue of recommen-
dations, a number of topics still need to be ad-
dressed: vaccine formulation, protection against 
O139 serotype, and efficacy in children and in 
HIV-positive individuals. Surveillance data should 
be available to determine the best timing for vac-
cination, define the population at risk, and moni-
tor the impact of interventions. Sustainable and 
cost-effective vaccination strategies should be de-
cided according to each specific situation. 
Decision-making tool for use of OCVs in 
complex emergencies
In accordance with these recommendations, an 
ad-hoc meeting was organized to finalize the deci-
sion-making tool for the use of OCVs in complex 
emergencies that was drafted during the confer-
ence (the full text can be found in Annexure 2). A 
three-step approach was adopted, the relevance 
of OCV-use being examined at each step:
a.  a risk assessment for an outbreak of cholera 
should be undertaken first;
b.  an assessment of whether key public-health 
priorities are or can be implemented in a time-
ly manner, combined with an analysis of the 
capacity to contain a possible outbreak; and
c.  an assessment of the feasibility of an immu-
nization campaign using OCVs.
This document, meant to be a convenient tool, in-
cludes many practical aspects of importance when Chaignat CL and Monti V Oral cholera vaccines in complex emergencies
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thinking of performing a vaccination campaign. 
Essential elements are reminded, such as the need 
to reinforce surveillance systems and to conduct 
vaccination campaigns concomitantly with other 
interventions, especially improvement of envi-
ronmental conditions. The Global Task Force on 
Cholera Control, at the WHO headquarters, will 
provide expertise and guidance whenever neces-
sary. Decision-makers should not hesitate to con-
tact the Task Force with any doubts or questions, 
or if envisaging the use of OCVs. 
This decision-making tool is now ready for field-
testing. Results and feedback will be included in 
an adapted version. WHO is willing to coordinate 
with institutions or governments interested in 
performing such studies. If OCVs are to be used 
as a public-health tool, now is the moment for 
decision-makers—ministries of health and gov-
ernments, NGOs and institutions, donors and 
stakeholders—to express their views of using this 
vaccine in the best interest of the innumerable 
populations affected by cholera. It cannot be 
conducted without advocacy, strong involvement, 
and resources. Sustainability, surveillance data, and 
a true knowledge on the burden of disease are also 
indispensable to effective interventions.
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(1) Recommendations for the use of OCV in 
complex emergency settings
Relevance and multidisciplinary approach:
The relevance of oral cholera vaccination should 
be examined in the light of other public health 
priorities. Among the top 10 priorities in emer-
gencies is the control of communicable diseases, 
which should always include a risk assessment 
for cholera.
If a cholera vaccination campaign is deemed nec-
essary after assessment of epidemic risk and public 
health priorities, water and sanitation programmes 
should be implemented before or concurrently 
with the vaccination campaign. Surveillance sys-
tems should be reinforced.
A high level commitment by all stakeholders and 
national authorities is critical.
Exclusion criteria for OCV use: 
Vaccination with the current internationally avail-
able prequalified vaccine is not recommended 
once a cholera outbreak has started.
An OCV campaign that would interfere with oth-
er critical public health interventions should not 
be carried out.
Other exclusion criteria include: very high mor-
tality from a range of causes; basic needs (food, 
shelter) not covered; an ongoing outbreak of an-
other disease; an untenable security situation.
Development of a decision-making tool for 
OCV use: 
A decision-making tool will help in determining 
the relevance of cholera vaccination in a given 
setting. A three-step process is proposed:
a risk assessment for a cholera outbreak, which 
should be undertaken first; 
an assessment of whether key public health prio-
rities  are  or  can  be  implemented  in  a  timely 
manner together with an analysis of the capaci-
ty to respond to a possible outbreak;
an assessment of the feasibility of an immuniza-
tion campaign.
The decision-making tool needs to be tested and 
validated in complex emergency settings.
(2) Recommendations for the use of OCV in 
endemic settings
Despite the limitations of the currently available 
vaccine identified in the public health context, 
the use of OCV in certain endemic situations1   
should be recommended and guidelines should 
be developed. Such use must be complementary 
to existing strategies for cholera control, such 
as safe water and sanitation, case management, 
and health education of the community.
Without jeopardizing the issue of recommen-
dations, a number of topics still need to be ad-
dressed. Recommendations can be modified ac-
cordingly, at a later stage:
Vaccines per se: 
New vaccines with improved “fieldability”2 and 
cost-effectiveness are needed. Their efficacy should 
be established in the field.
Where the O139 serotype is responsible for a sig-
nificant proportion of cholera cases, O139 should 
be included in the OCV.
Documentation of OCV efficacy is needed in chil-
dren and in HIV-positive individuals.
Surveillance, endemicity and seasonality: 
Criteria for a definition of endemicity should be 
established.
Studies should be conducted to determine the 
best timing for vaccination (seasonality, baseline 
data, etc.) in order to enhance the protection of 
the population. Past experience has shown that 
a two-dose vaccine cannot be used once an out-
break has started.
Vaccination campaigns should be accompanied 
by surveillance to define the population at risk 
and to monitor the impact of vaccination pro-
grammes (e.g. among particular age groups and 
spatial clusters).
1A definition of endemicity of: one or more cholera cases/1000 population at risk per year has been proposed, 
but no consensus was reached.
2To be understood as the practicability of the vaccine when used in difficult field conditions.
Annexure 1 
Recommendations (3)Chaignat CL and Monti V Oral cholera vaccines in complex emergencies
Volume 25 | Number 2 | June 2007 255
Vaccination strategies:
Vaccination strategies should aim for the high-
est possible vaccination coverage to realize the 
benefits of herd protection; strategies should be 
examined and defined according to each specific 
situation. Characteristics of the currently avail-
able OCV (age group, formulation, etc.) make it 
difficult to include the vaccine in routine EPI.
The cost-effectiveness, sustainability, and econom-
ic viability of vaccination strategies should be 
assessed at country level.
Additional recommendations for WHO:
•  Develop a decision-making tool and guide-
lines for use of OCV (1) in complex emergen-
cies and (2) in endemic settings. An ad-hoc 
working group will be established to develop 
the draft risk assessment and decision-mak-
ing tool further; the first draft was to be avail-
able for circulation among the meeting par-
ticipants by the end of February 2006. After 
revision, the document would be submitted 
to partners, including meeting participants, 
and countries.
•  Test and validate the draft decision-making 
tool in field conditions, at community level.
•  Identify possible sites for implementation 
projects, as a follow-up to the demonstration 
projects already carried out between 2002 
and 2005.
•  Ensure regular meetings for review and guid-
ance.
•  Develop an information and advocacy strate-
gy for regional offices, country offices, coun-
tries and potential donors.
•  Identify funding sources.Chaignat CL and Monti V Oral cholera vaccines in complex emergencies
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Introduction
The aim of the decision-making tool described 
in this annex is to help determine the relevance 
of OCV use for mass immunization campaigns 
in the context of complex emergencies. For this 
purpose, complex emergencies are defined as 
situations in which:
•  a large part of the population is affected, lead-
ing  to  potential  massive  population  move-
ments;
•  the coping capacities of local and national 
authorities are overwhelmed by the magni-
tude of the man-made or natural disaster;
•  numerous national and international actors 
may participate in the relief effort.
While this tool can be used in other crisis situ-
ations,  WHO  plans  another  document—to  be 
published  shortly—on  the  use  of  OCV  in  en-
demic settings.
The decision-making process follows a three-
step approach (see Figure A1.1), with the rele-
vance of OCV use being examined at each step:
•  a risk assessment for a cholera outbreak, which 
should be undertaken first; 
•  an assessment of whether key public health 
priorities are or can be implemented in a time-
ly manner, combined with an analysis of the 
capacity to contain a possible outbreak;
•  an assessment of the feasibility of an immu-
nization campaign using OCV.
Relevance of OCV use: 
During the course of a complex emergency, the 
following public health aspects should be taken 
into account when examining the relevance of 
the potential use of OCV:
•  The top 10 public health priorities in emer-
gencies1 include the control of communicable 
diseases: a risk assessment for cholera should 
always be part of the initial assessment.
•  Regardless of whether or not OCV is used, 
access to sufficient safe water and adequate 
sanitation should be ensured.
Fig. A1.1. Decision-making tree
Decision-making tree  for 
OCV use in complex emergencies
Step 1
Step 2
Step 3
Risk of cholera outbreak Limited risk
Risk exists
Limited capacity
Capacity to contain potential outbreak
Feasibility of OCV
mass vaccination campaign 
Not feasible 
Feasible
Immunization can be considered
OCV use
not relevant 
OCV use 
not relevant
OCV use
not relevant 
Good coping/
response capacities
Annexure 2
Decision-making tool for the use of oral cholera vaccines in complex emergencies (3)
1See WHO/HAC : http://www.who.int/mediacentre/factsheets/fs090/en/ for details.Chaignat CL and Monti V Oral cholera vaccines in complex emergencies
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•  Priority should be given to other health prio-
rities when. 
•  mortality is very high (above the emergency 
threshold of 1/10 000 per day);
•  basic needs (food, shelter, basic health serv-
ices, and security) are not met;.
•  an outbreak of another disease is ongoing.
•  With the currently available internationally 
prequalified vaccine,2 vaccination is not rec-
ommended in an area where an outbreak has 
already started.
The relevance of oral cholera vaccination should 
therefore be examined in the light of all public 
health priorities identified.
Remarks
Each step of the decision-making process should 
be assessed carefully and each element linked 
with the next, as shown in the decision-making 
tree (Figure A1.1).
The Global Task Force on Cholera Control, at WHO 
headquarters, will provide expertise and guidance 
whenever necessary. Decision-makers should not 
hesitate to contact the Task Force with any doubts 
or questions. 
A high level of political commitment by all 
stakeholders and national authorities is critical.
If a decision is made to conduct a cholera vac-
cination  campaign,  water  and  sanitation  pro-
grammes should be implemented before (or at 
least concurrently with) vaccination. A surveil-
lance system—including laboratory capacity to 
diagnose cholera and basic health education for 
communities—should also be implemented 
before a mass cholera vaccination campaign is 
started.
2Whole-cell killed V. cholerae O1 with purified recombinant B-subunit of cholera toxin (WC/rBS), administered in 
two doses, 10–14 days apart, in 150 ml of water mixed with a buffer.Chaignat CL and Monti V Oral cholera vaccines in complex emergencies
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Criteria  Factors to consider For example 
Epidemiology  1. Endemicity 1. Natural immunity, e.g. have there been any cases 
detected within the previous five years?
2. Risk of introduction  2. Displacement, population movements from an 
endemic area
3. Seasonality 3. Beginning/end of peak season
Water supply  1. Current access to 
sufficient quantity 
of safe water 
2. Capacity and timing 
to reach and main-
tain standards
1. According to Sphere standards (see http://www.
sphereproject.org/handbook/index.htm),  number 
of litres per person per day, quantity and quality 
of water chlorination, water trucks, water pipes, 
wells, etc. Risk of water supply becoming contami-
nated with V. cholerae
2. Poor disinfection practices, poor water-handling 
practices Low likelihood of protecting water 
supplies and reaching high level of disinfection 
before outbreak
Sanitation 1. Current access and 
use 
2. Capacity and timing 
to reach and main-
tain standards
1. According to Sphere standards, number of persons/
latrine, waste management, etc.
2. Latrines ‘turnover’, space to build new latrines
Hygiene 1. Levels of personal 
and food hygiene
1. Lack of adequate quantities of water for washing. 
Availability of soap for hand-washing. Poor food 
hygiene practices
Population/ 
demography
1. Density 
2. Vulnerability
3. Closed/open  
settings
1. Square metres per person according to Sphere 
standards. Number of persons per household and 
average household size
2. Disrupted living conditions, specific vulnerable 
groups, long period of flight from conflict, leading 
to stress and malnutrition
3. Closed settings, such as detention centres or refu-
gee camps, with control of population movements
Community  1. Sociocultural behav-
iours
1. Level of education, hygiene practices, funeral prac-
tices, seasonal social and religious gatherings
1. Assessment of risk of outbreak of cholera
2. Assessment of the capacity to contain a potential outbreak
Components of 
response
Factors to consider For example 
Magnitude of 
outbreak
1. Size of affected area
2. Closed/open setting
1. Towns, open areas
2. Refugee camps, detention centres
Roads, communi-
cation routes
1. Potential for spread of outbreak 
along communication routes
1. Large outbreak affecting several locations
    Closed refugee settingChaignat CL and Monti V Oral cholera vaccines in complex emergencies
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Healthcare  1. Infrastructure
2. Human resources
 
3. Accessibility 
4. Supplies
1. Permanent, temporary, possibility to set 
up cholera treatment centres (CTCs) and 
oral rehydration units (ORUs), separate 
ward in the hospital
2. Healthcare staff, support staff, cleaners, 
cooks
3. 24 hours/day or not, distance, remoteness
4. Oral rehydration solution, infusion, Ring-
er’s lactate, cholera cots, cleaning mate-
rial, buckets, soap
Health education 1. Human resources and social 
network
2. Accessibility 
3. Supplies
1. NGOs, schools, associations, religious 
leaders, persons able to transmit the right 
message
2. Possibility to reach the population, trans-
port, cultural acceptance
3. Banners, leaflets, loudspeakers, etc.
Water and 
sanitation
Capacity to provide/improve/
reinforce as needed in terms of 
quantity and quality
1. Human resources
2. Supplies
3. Technical component
4. Accessibility
Capacity to adequately disinfect drinking-
water supplies, to reach minimal coverage 
with sanitary facilities, and to provide ad-
equate water and soap for personal hygiene 
before outbreak
1. Trained technical personnel, able to set up 
and maintain systems
2. Ability to find rapidly on the local market 
material, such as cement, pipes, soap
3. Ability to use appropriate technology accord-
ing to locally-available material,
    technical knowledge and cultural accept-
ability
4. Distance to water source and to latrines, 
access 24 hours/day or not
Surveillance 
system 
Capacity to ensure early detec-
tion and monitoring of out-
breaks
1. Alert system within the com-
munity
2. Surveillance system
3. Diagnosis, laboratory confir-
mation
1. Reaction capacity, (tele) communications
2. Trained human resources, data manage-
ment
3. Trained human resources, laboratory, sup-
plies
National and 
local authorities
1. Local governance systems
2. Management
3. Inter-sectoral coordination 
1. Camp management, detaining authorities, 
local authorities
2. At all levels of intervention
3. Partnership, coordination meetings
NGOs=Non-governmental organizationsChaignat CL and Monti V Oral cholera vaccines in complex emergencies
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Elements to assess Factors to consider For example 
Vaccines (currently 
pre-qualified OCV) 
+ buffer
1. Availability of good-quality 
products, shelf-life
2. Timing to arrive on site
3. Regulatory approval
4. Price
1. Possible production within a given 
timeframe
2. International and local transport
3. In the importing country, customs 
regulations, etc.
4. Currently up to US$ 8 per dose
Vaccines (potential 
new vaccines) 
1. Availability of good-quality 
products
2. Timing to arrive on site
3. Regulatory approval
4. Ease of use/formulation
5. Price
1. Potential manufacturers 
2. International and local transport
3. Pre-qualification process
4. Single-dose, easy-to-use vaccine
5. Inexpensive vaccine and related material
Access 1. Roads, airstrips
2. Security
3. Climatic conditions
1. Road conditions, distance
2. Conflict, landmines, checkpoints, etc.
3. Rainy season, earthquakes, etc.
Population 1. Size 
2. Target population
3. Stability
4. Acceptability
5. Strong social network 
1. To evaluate with precision
2. Criteria for selection (sub-groups, vul-
nerability, etc); % of the population to 
reach; how to respect the targeting?
3. Guarantee to have the same people 
for the two doses (limited movements 
in and out), accessibility to the popu-
lation
4. No strong expressed opposition, cultural 
awareness, risk of social stigmatization?
5. To inform and mobilize the commu-
nity
Logistics (for 
10,000 people)*
1. Transport and storage capac-
ity
2. Cold-chain capacity 
3. Equipment and supplies
4. Telecommunication 
5. Waste management
1. International and local transport of 
vaccines and related material by truck, 
aircraft, etc., up to vaccination posts
2. To be assessed carefully; usually dif-
ficult to find in sufficient space and 
volume
3. Clean water in large quantity, paper, 
pens, cups, buckets, etc.
4. To maintain contact with and supervi-
sion of vaccination teams (telephone, 
radio, satellite telephones, e-mails, 
etc.)
5. Appropriate waste points, glass re-
cycling facilities (usually difficult to 
find)
Resources 1. Human resources: number,  
training, training capacity
2. Financial resources
3. Partners and coordination
1. Vaccination teams, team leaders, 
supervisors
2. Vaccines, transport, per-diem payments, 
cold-chain, supplies, etc.
3. Ministry of health, NGOs, local partners, 
community. Establish  responsibilities 
and close monitoring throughout the 
implementation
3. Assessment of the feasibility of an OCV campChaignat CL and Monti V Oral cholera vaccines in complex emergencies
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Outline of imple-
mentation plan
1. Well-defined target popula-
tion
2. Detailed strategy, including 
realistic timing, and resourc-
es needed
1. People with less access to safe water; 
people with poor sanitation facilities; 
people with limited access to health-
care
Monitoring capac-
ity
1. Monitoring the implementa-
tion
2. Monitoring the outpost 
3. Follow-up of the epide-
miological and biological 
surveillance
1. Strong monitoring and close supervi-
sion needed
2. Vaccination coverage
3. Case control, number of vaccinated vs 
non-vaccinated people with confirmed 
cholera
*For 10,000 people: total weight and storage volume of vaccine vials, buffer, plastic cups, and water 
are about: 3,700 kg and 8.1 m3; without the water, weight is only 422.5 kg and volume 3.5 m3
NGOs=Non-governmental organizations; OCV=Oral cholera vaccine